Diagnostic performance of F-18 FDG PET for detection of cardiac sarcoidosis; A systematic review and meta-analysis

  • Seong-Jang KimEmail author
  • Kyoungjune Pak
  • Keunyoung Kim
Original Article



The purpose of the current study was to investigate the diagnostic performance of F-18 fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) for diagnosis of cardiac sarcoidosis (CS) through a systematic review and meta-analysis.


The PubMed and EMBASE database, from the earliest available date of indexing through 31 March 31, 2018, were searched for studies evaluating the diagnostic performance of F-18 FDG PET or PET/CT for CS. We determined the sensitivities and specificities across studies, calculated positive and negative likelihood ratios (LR+ and LR−), and constructed summary receiver operating characteristic (SROC) curves.


Across 17 studies (891 patients), the pooled sensitivity was 0.84 [95% confidence interval (95% CI) 0.71-0.91] with heterogeneity (I2 = 77.5) and a pooled specificity of 0.83 (95% CI 0.74-0.89) with heterogeneity (I2 = 80.0). Likelihood ratio (LR) syntheses gave an overall LR+ of 4.9 (95% CI 3.3-7.3) and LR− of 0.2 (95% CI 0.11-0.35). The pooled diagnostic odds ratio was 27 (95% CI 14-55). Hierarchical SROC curve indicates that the area under the curve was 0.90 (95% CI 0.87-0.92). Meta-regression showed that combined myocardial perfusion imaging was the source of heterogeneity.


The current meta-analysis showed the moderate sensitivity and specificity of F-18 FDG PET or PET/CT for diagnosis of CS. The presence of combined myocardial perfusion imaging could improve diagnostic accuracy of F-18 FDG PET or PET/CT for diagnosis of CS. At present, the literature regarding the use of F-18 FDG PET for detection of CS remains limited; thus, further large multicenter studies would be necessary to substantiate the diagnostic accuracy of F-18 FDG PET for diagnosis of CS.


F-18 FDG PET/CT sarcoidosis diagnosis 



Cardiac sarcoidosis


Diagnostic odds ratio


Endomyocardial biopsy






Japanese Ministry of Health and Welfare


Positron emission tomography


Positron emission tomography/computed tomography


Maximum standardized uptake value


Author’s Contribution

Protocol/project development: Kim SJ, Pak K. Data collection or management: Kim SJ, Kim K, Pak K. Data analysis: Kim SJ, Kim K. Manuscript writing/editing; Kim SJ, Pak K, and Kim K.


The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of this study.

Ethical Approval

Institutional Review Board approval was not required because we only performed data analysis based on the published studies.

Informed Consent

Written informed consent was not required for this study because it is a meta-analysis based on the studies that have been published.

Supplementary material

12350_2018_1582_MOESM1_ESM.pptx (422 kb)
Supplementary material 1 (PPTX 422 kb) Supplementary Figure 1. Forest plots of diagnostic performance of F-18 FDG PET or PET/CT based on the use of myocardial perfusion imaging.
12350_2018_1582_MOESM2_ESM.jpg (822 kb)
Supplementary material 2 (JPEG 821 kb)


  1. 1.
    Newman LS, Rose CS, Maier LA. Sarcoidosis. N Engl J Med 1997;336:1224-34.CrossRefGoogle Scholar
  2. 2.
    Patel MR, Cawley PJ, Heitner JF, Klem I, Parker MA, Jaroudi WA, et al. Detection of myocardial damage in patients with sarcoidosis. Circulation 2009;120:1969-77.CrossRefGoogle Scholar
  3. 3.
    Dubrey SW, Falk RH. Diagnosis and management of cardiac sarcoidosis. Prog Cardiovasc Dis 2010;52:336-46.CrossRefGoogle Scholar
  4. 4.
    Betensky BP, Tschabrunn CM, Zado ES, Goldberg LR, Marchlinski FE, Garcia FC, et al. Long-term follow-up of patients with cardiac sarcoidosis and implantable cardioverter-defibrillators. Heart Rhythm 2012;9:884-91.CrossRefGoogle Scholar
  5. 5.
    Silverman KJ, Hutchins GM, Bulkley BH. Cardiac sarcoid: a clinicopathologic study of 84 unselected patients with systemic sarcoidosis. Circulation 1978;58:1204-11.CrossRefGoogle Scholar
  6. 6.
    Sharma OP, Maheshwari A, Thaker K. Myocardial sarcoidosis. Chest 1993;103:253-8.CrossRefGoogle Scholar
  7. 7.
    Birnie DH, Nery PB, Ha AC, Beanlands RS. Cardiac sarcoidosis. J Am Coll Cardiol 2016;68:411-21.CrossRefGoogle Scholar
  8. 8.
    Robert WC, McAllister HA, Ferrans VJ. Sarcoidosis of the heart. Am J Med 1977;63:86-108.CrossRefGoogle Scholar
  9. 9.
    Leone O, Veinot JP, Angelini A, Baandrup UT, Basso C, Berry G, et al. 2011 Consensus statement on endomyocardial biopsy from the Association for European Cardiovascular Pathology and the Society for Cardiovascular Pathology. Cardiovasc Pathol 2012;21:245-74.CrossRefGoogle Scholar
  10. 10.
    Uemura A, Morimoto S, Hiramitsu S, Kato Y, Ito T, Hishida H. Histologic diagnostic rate of cardiac sarcoidosis: Evaluation of endomyocardial biopsies. Am Heart J 1999;138:299-302.CrossRefGoogle Scholar
  11. 11.
    Diagnostic standard and guidelines for sarcoidosis. Jpn J Sarcoidosis Granulomatous Disord 2007;27:89-102.Google Scholar
  12. 12.
    Youssef G, Leung E, Mylonas I, Nery P, Williams K, Wisenberg G, et al. The use of 18F-FDG PET in the diagnosis of cardiac sarcoidosis: A systematic review and metaanalysis including the Ontario experience. J Nucl Med 2012;53:241-8.CrossRefGoogle Scholar
  13. 13.
    Ishida Y, Yoshinaga K, Miyagawa M, Moroi M, Kondoh C, Kiso K, et al. Recommendations for 18F-fluorodeoxyglucose positron emission tomography imaging for cardiac sarcoidosis: Japanese Society of Nuclear Cardiology recommendations. Ann Nucl Med 2014;28:393-403.CrossRefGoogle Scholar
  14. 14.
    Ishimaru S, Tsujino I, Takei T, Tsukamoto E, Sakaue S, Kamigaki M, et al. Focal uptake on 18F-fluoro-2-deoxyglucose positron emission tomography images indicates cardiac involvement of sarcoidosis. Eur Heart J 2005;26:1538-43.CrossRefGoogle Scholar
  15. 15.
    Blankstein R, Osborne M, Naya M, Waller A, Kim CK, Murthy VL, et al. Cardiac positron emission tomography enhances prognostic assessments of patients with suspected cardiac sarcoidosis. J Am Coll Cardiol 2014;63:329-36.CrossRefGoogle Scholar
  16. 16.
    Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS-2: A revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 2011;155:529-36.CrossRefGoogle Scholar
  17. 17.
    Glas AS, Lijmer JG, Prins MH, Bonsel GJ, Bossuyt PM. The diagnostic odds ratio: A single indicator of test performance. J Clin Epidemiol 2003;56:1129-35.CrossRefGoogle Scholar
  18. 18.
    Thompson SG. Why sources of heterogeneity in meta-analysis should be investigated. BMJ 1994;309:1351-5.CrossRefGoogle Scholar
  19. 19.
    Deeks JJ, Macaskill P, Irwig L. The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. J Clin Epidemiol 2005;58:882-93.CrossRefGoogle Scholar
  20. 20.
    Hamza TH, van Houwelingen HC, Stijnen T. The binomial distribution of meta-analysis was preferred to model within-study variability. J Clin Epidemiol 2008;61:41-51.CrossRefGoogle Scholar
  21. 21.
    Reitsma JB, Glas AS, Rutjes AW, Scholten RJ, Bossuyt PM, Zwinderman AH. Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. J Clin Epidemiol 2005;58:982-90.CrossRefGoogle Scholar
  22. 22.
    Rutter CM, Gatsonis CA. A hierarchical regression approach to meta-analysis of diagnostic test accuracy evaluations. Stat Med 2001;20:2865-84.CrossRefGoogle Scholar
  23. 23.
    Lijmer JG, Mol BW, Heisterkamp S, Bonsel GJ, Prins MH, van der Meulen JH, et al. Empirical evidence of design-related bias in studies of diagnostic tests. JAMA 1999;282:1061-6.CrossRefGoogle Scholar
  24. 24.
    Stengel D, Bauwens K, Sehouli J, Ekkernkamp A, Porzsolt F. A likelihood ratio approach to meta-analysis of diagnostic studies. J Med Screen 2003;10:47-51.CrossRefGoogle Scholar
  25. 25.
    Leeflang MM, Deeks JJ, Gatsonis C, Bossuyt PM, Cochrane Diagnostic Test Accuracy Working Group. Systematic reviews of diagnostic test accuracy. Ann Intern Med 2008;149:889-97.CrossRefGoogle Scholar
  26. 26.
    Ahmadian A, Brogan A, Berman J, Sverdlov AL, Mercier G, Mazzini M, et al. Quantitative interpretation of FDG PET/CT with myocardial perfusion imaging increases diagnostic information in the evaluation of cardiac sarcoidosis. J Nucl Cardiol 2014;21:925-39.CrossRefGoogle Scholar
  27. 27.
    Ambrosini V, Zompatori M, Fasano L, Nanni C, Nava S, Rubello D, Fanti S. 18F-FDG PET/CT for the assessment of disease extension and activity in patients with sarcoidosis: Results of a preliminary prospective study. Clin Nucl Med 2013;38:e171-7.CrossRefGoogle Scholar
  28. 28.
    Gormsen LC, Haraldsen A, Kramer S, Dias AH, Kim WY, Borghammer P. A dual tracer 68Ga-DOTANOC PET/CT and 18F-FDG PET/CT pilot study for detection of cardiac sarcoidosis. EJNMMI Res 2016;6:52.CrossRefGoogle Scholar
  29. 29.
    Ito K, Okazaki O, Morooka M, Kubota K, Minamimoto R, Hiroe M. Visual findings of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with cardiac sarcoidosis. Intern Med 2014;53:2041-9.CrossRefGoogle Scholar
  30. 30.
    Langah R, Spicer K, Gebregziabher M, Gordon L. Effectiveness of prolonged fasting 18F-FDG PET–CT in the detection of cardiac sarcoidosis. J Nucl Cardiol 2009;16:801-10.CrossRefGoogle Scholar
  31. 31.
    Manabe O, Yoshinaga K, Ohira H, Sato T, Tsujino I, Yamada A, et al. Right ventricular 18F-FDG uptake is an important indicator for cardiac involvement in patients with suspected cardiac sarcoidosis. Ann Nucl Med 2014;28:656-63.CrossRefGoogle Scholar
  32. 32.
    Momose M, Fukushima K, Kondo C, Serizawa N, Suzuki A, Abe K, et al. Diagnosis and detection of myocardial injury in active cardiac sarcoidosis—significance of myocardial fatty acid metabolism and myocardial perfusion mismatch. Circ J 2015;79:2669-76.CrossRefGoogle Scholar
  33. 33.
    Norikane T, Yamamoto Y, Maeda Y, Noma T, Dobashi H, Nishiyama Y. Comparative evaluation of 18F-FLT and 18F-FDG for detecting cardiac and extra-cardiac thoracic involvement in patients with newly diagnosed sarcoidosis. EJNMMI Res 2017;7:69.CrossRefGoogle Scholar
  34. 34.
    Ohira H, Tsujino I, Ishimaru S, Oyama N, Takei T, Tsukamoto E, et al. Myocardial imaging with 18F-fluoro-2-deoxyglucose positron emission tomography and magnetic resonance imaging in sarcoidosis. Eur J Nucl Med Mol Imaging 2008;35:933-41.CrossRefGoogle Scholar
  35. 35.
    Okumura W, Iwasaki T, Toyama T, Iso T, Arai M, Oriuchi N, et al. Usefulness of fasting 18F-FDG PET in identification of cardiac sarcoidosis. J Nucl Med 2004;45:1989-98.Google Scholar
  36. 36.
    Schildt JV, Loimaala AJ, Hippeläinen ET, Ahonen AA. Heterogeneity of myocardial 2-[18F]fluoro-2-deoxy-d-glucose uptake is a typical feature in cardiac sarcoidosis: A study of 231 patients. Eur Heart J Cardiovasc Imaging 2018;19:293-8.CrossRefGoogle Scholar
  37. 37.
    Soussan M, Brillet PY, Nunes H, Pop G, Ouvrier MJ, Naggara N, et al. Clinical value of a high-fat and low-carbohydrate diet before FDG-PET/CT for evaluation of patients with suspected cardiac sarcoidosis. J Nucl Cardiol 2013;20:120-7.CrossRefGoogle Scholar
  38. 38.
    Tahara N, Tahara A, Nitta Y, Kodama N, Mizoguchi M, Kaida H, et al. Heterogeneous myocardial FDG uptake and the disease activity in cardiac sarcoidosis. JACC Cardiovasc Imaging 2010;3:1219-28.CrossRefGoogle Scholar
  39. 39.
    Yokoyama R, Miyagawa M, Okayama H, Inoue T, Miki H, Ogimoto A, et al. Quantitative analysis of myocardial 18F-fluorodeoxyglucose uptake by PET/CT for detection of cardiac sarcoidosis. Int J Cardiol 2015;195:180-7.CrossRefGoogle Scholar
  40. 40.
    Boerman OC, Rennen H, Oyen WJ, Corstens FH. Radiopharmaceuticals to image infection and inflammation. Semin Nucl Med 2001;31:286-95.CrossRefGoogle Scholar
  41. 41.
    Zhuang H, Alavi A. 18-Fluorodeoxyglucose positron emission tomographic imaging in the detection and monitoring of infection and inflammation. Semin Nucl Med 2002;32:47-59.CrossRefGoogle Scholar
  42. 42.
    Love C, Tomas MB, Tronco GG, Palestro CJ. FDG PET of infection and inflammation. Radiographics 2005;25:1357-68.CrossRefGoogle Scholar
  43. 43.
    Takeda N, Yokoyama I, Hiroi Y, Sakata M, Harada T, Nakamura F, et al. Positron emission tomography predicted recovery of complete A-V nodal dysfunction in a patient with cardiac sarcoidosis. Circulation 2002;105:1144-5.CrossRefGoogle Scholar
  44. 44.
    Ishimaru S, Tsujino I, Sakaue S, Oyama N, Takei T, Tsukamoto E, et al. Combination of 18F-fluoro-2-deoxyglucose positron emission tomography and magnetic resonance imaging in assessing cardiac sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2005;22:234-5.Google Scholar
  45. 45.
    Tang R, Wang JT, Wang L, Le K, Huang Y, Hickey AJ, et al. Impact of patient preparation on the diagnostic performance of 18F-FDG PET in cardiac sarcoidosis: A systematic review and meta-analysis. Clin Nucl Med 2016;41:e327-39.CrossRefGoogle Scholar
  46. 46.
    Ding HJ, Shiau YC, Wang JJ, Ho ST, Kao A. The influences of blood glucose and duration of fasting on myocardial glucose uptake of [18F]fluoro-2-deoxy-d-glucose. Nucl Med Commun 2002;23:961-5.CrossRefGoogle Scholar
  47. 47.
    Williams G, Kolodny GM. Suppression of myocardial 18F-FDG uptake by preparing patients with a high-fat, low-carbohydrate diet. Am J Roentgenol 2008;190:W151-6.CrossRefGoogle Scholar
  48. 48.
    Guideline for diagnosis of cardiac sarcoidosis: Study report on diffuse pulmonary diseases. Tokyo: Ministry of Health, Labour and Welfare; 1993. p. 23-4.Google Scholar
  49. 49.
    Skali H, Schulman AR, Dorbala S. 18F-FDG PET/CT for the assessment of myocardial sarcoidosis. Curr Cardiol Rep 2013;15:352.CrossRefGoogle Scholar
  50. 50.
    Dilsizian V, Bacharach SL, Beanlands RS, et al. ASNC imaging guidelines/SNMMI procedure standard for positron emission tomography (PET) nuclear cardiology procedures. J Nucl Cardiol 2016;23:1187-226.CrossRefGoogle Scholar
  51. 51.
    Lee PI, Cheng G, Alavi A. The role of serial FDG PET for assessing therapeutic response in patients with cardiac sarcoidosis. J Nucl Cardiol 2017;24:19-28.CrossRefGoogle Scholar
  52. 52.
    Ahmadian A, Pawar S, Govender P, Berman J, Ruberg FL, Miller EJ. The response of FDG uptake to immunosuppressive treatment on FDG PET/CT imaging for cardiac sarcoidosis. J Nucl Cardiol 2017;24:413-24.CrossRefGoogle Scholar
  53. 53.
    Muser D, Santangeli P, Castro SA, et al. Prognostic role of serial quantitative evaluation of 18F-fluorodeoxyglucose uptake by PET/CT in patients with cardiac sarcoidosis presenting with ventricular tachycardia. Eur J Nucl Med Mol Imaging 2018;45:1394-404.CrossRefGoogle Scholar
  54. 54.
    Flores RJ, Flaherty KR, Jin Z, Bokhari S. The prognostic value of quantitating and localizing F-18 FDG uptake in cardiac sarcoidosis. J Nucl Cardiol 2018. (Epub ahead of print0.Google Scholar

Copyright information

© American Society of Nuclear Cardiology 2019

Authors and Affiliations

  • Seong-Jang Kim
    • 1
    • 2
    • 3
    Email author
  • Kyoungjune Pak
    • 4
  • Keunyoung Kim
    • 4
  1. 1.Department of Nuclear MedicinePusan National University Yangsan HospitalYangsanKorea
  2. 2.BioMedical Research Institute for Convergence of Biomedical Science and TechnologyPusan National University Yangsan HospitalYangsanKorea
  3. 3.Department of Nuclear Medicine, College of MedicinePusan National UniversityYangsanKorea
  4. 4.Department of Nuclear MedicinePusan National University HospitalPusanKorea

Personalised recommendations